{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T11:35:08Z","timestamp":1775907308189,"version":"3.50.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T00:00:00Z","timestamp":1693267200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Fibrodysplasia ossificans progressive (FOP) is an ultra-rare genetic disorder that is caused by a mutation in the <jats:italic>ACVR1<\/jats:italic> gene and provokes severe heterotopic ossification. Since flares of the disease are associated with inflammation, it is assumed that JAK inhibitors can control active FOP due to blocking multiple signaling pathways.<\/jats:p>","DOI":"10.1186\/s12969-023-00856-1","type":"journal-article","created":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T09:02:29Z","timestamp":1693299749000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Successful experience of tofacitinib treatment in patients with Fibrodysplasia Ossificans Progressiva"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1842-0348","authenticated-orcid":false,"given":"Irina P.","family":"Nikishina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9803-0221","authenticated-orcid":false,"given":"Svetlana V.","family":"Arsenyeva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3815-0608","authenticated-orcid":false,"given":"Valeria G.","family":"Matkava","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4156-5062","authenticated-orcid":false,"given":"Alia N.","family":"Arefieva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-6826","authenticated-orcid":false,"given":"Mariya I.","family":"Kaleda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7418-9369","authenticated-orcid":false,"given":"Alexandr V.","family":"Smirnov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4503-7750","authenticated-orcid":false,"given":"Leonid M.","family":"Blank","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1180-8086","authenticated-orcid":false,"given":"Mikhail M.","family":"Kostik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,29]]},"reference":[{"issue":"1","key":"856_CR1","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.berh.2007.11.007","volume":"22","author":"FS Kaplan","year":"2008","unstructured":"Kaplan FS, Le Merrer M, Glaser DL, Pignolo RJ, Goldsby RE, Kitterman JA, et al. Fibrodysplasia ossificans progressiva. Best Pract Res Clin Rheumatol. 2008;22(1):191\u2013205. https:\/\/doi.org\/10.1016\/j.berh.2007.11.007.","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"856_CR2","doi-asserted-by":"publisher","unstructured":"Barruet E, Morales BM, Cain CJ, Ton AN, Wentworth KL, Chan TV, Moody TA, Haks MC, Ottenhoff TH, Hellman J, Nakamura MC, Hsiao EC. NF-\u03baB\/MAPK activation underlies ACVR1-mediated inflammation in human heterotopic ossification. JCI Insight 2018 Nov 15;3(22):e122958. doi: https:\/\/doi.org\/10.1172\/jci.insight.122958.","DOI":"10.1172\/jci.insight.122958"},{"key":"856_CR3","doi-asserted-by":"publisher","unstructured":"Barruet E, Morales BM, Lwin W, White MP, Theodoris CV, Kim H, Urrutia A, Wong SA, Srivastava D, Hsiao EC. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1\/5\/8 signaling. Stem Cell Res Ther 2016 Aug 17;7(1):115. doi: https:\/\/doi.org\/10.1186\/s13287-016-0372-6. PMID: 27530160; PMCID: PMC4988052.","DOI":"10.1186\/s13287-016-0372-6"},{"key":"856_CR4","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.55563\/clinexprheumatol\/d4q71b","volume":"39","author":"I Nikishina","year":"2021","unstructured":"Nikishina I, Arsenyeva S, Matkava V, Arefieva A, Pachkoria T. Unexpected clinical findings as evidence of the relation of Fibrodysplasia ossificans progressiva to axial spondyloarthritis. Clin Exp Rheumatol. 2021;39:1149\u2013263. P177.","journal-title":"Clin Exp Rheumatol"},{"key":"856_CR5","doi-asserted-by":"publisher","unstructured":"Pignolo RJ, McCarrick-Walmsley R, Wang H, Qiu S, Hunter J, Barr S, He K, Zhang H, Kaplan FS. Plasma-soluble biomarkers for Fibrodysplasia Ossificans Progressiva (FOP) reflect Acute and Chronic Inflammatory States. J Bone Miner Res 2022 Mar;37(3):475\u201383. doi: https:\/\/doi.org\/10.1002\/jbmr.4492. Epub 2022 Jan 24.","DOI":"10.1002\/jbmr.4492"},{"issue":"1","key":"856_CR6","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12969-019-0386-6","volume":"17","author":"R Haviv","year":"2019","unstructured":"Haviv R, Moshe V, De Benedetti F, Prencipe G, Rabinowicz N, Uziel Y. Is fibrodysplasia ossificans progressiva an interleukin-1 driven auto-inflammatory syndrome? Pediatr Rheumatol Online J. 2019;17(1):21. https:\/\/doi.org\/10.1186\/s12969-019-0386-6.","journal-title":"Pediatr Rheumatol Online J"},{"key":"856_CR7","doi-asserted-by":"publisher","unstructured":"Matkava V, Nikishina I, Arsenyeva S, Kaleda M, Samarkina E, Cherkasova M et al. Preliminary results of the inflammatory biomarkers measurement in patients with fibrodysplasia ossificans progressiva in compare to systemic juvenile idiopathic arthritis. In: Pediatr Rheumatol 20 (Suppl 2): 20 Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022); 2022 Sep 20\u201323; Prague, Czech Republic. P257, https:\/\/doi.org\/10.1186\/s12969-022-00729-z.","DOI":"10.1186\/s12969-022-00729-z"},{"issue":"10315","key":"856_CR8","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)01255-1","volume":"398","author":"N Ruperto","year":"2021","unstructured":"Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, Paediatric Rheumatology International Trials Organisation (PRINTO) and Pediatric Rheumatology Collaborative Study Group (PRCSG), et al. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet. 2021;398(10315):27. https:\/\/doi.org\/10.1016\/S0140-6736(21)01255-1.","journal-title":"Lancet"},{"key":"856_CR9","doi-asserted-by":"publisher","unstructured":"Kaplan FS, Al Mukaddam M, Pignolo RJ. A cumulative analogue joint involvement scale (CAJIS) for fibrodysplasia ossificans progressiva (FOP). Bone. 2017 Aug;101:123\u2013128. doi: https:\/\/doi.org\/10.1016\/j.bone.2017.04.015. Epub 2017 Apr 29. PMID: 28465250.","DOI":"10.1016\/j.bone.2017.04.015"},{"key":"856_CR10","first-page":"1","volume":"2","author":"FS Kaplan","year":"2022","unstructured":"Kaplan FS, et al. The medical management of fibrodysplasia ossificans progressiva: current treatment considerations. Proc Intl Clin Council FOP. 2022;2:1\u2013127. Available online at:. https:\/\/d3n8a8pro7vhmx.cloudfront.net\/ifopa\/pages\/1042\/attachments\/original\/1654014231\/GUIDELINES__updated_May_2022.pdf?1654014231.","journal-title":"Proc Intl Clin Council FOP"},{"key":"856_CR11","doi-asserted-by":"publisher","unstructured":"Su\u0142ko J, Ebisz M, Bie\u0144 S, B\u0142a\u017ckiewicz M, Jurczyk M, Namy\u015blak M. Treatment of chronic recurrent multifocal osteomyelitis with bisphosphonates in children. Joint Bone Spine. 2019 Nov;86(6):783\u20138. https:\/\/doi.org\/10.1016\/j.jbspin.2019.06.005. Epub 2019 Jun 16.","DOI":"10.1016\/j.jbspin.2019.06.005"},{"key":"856_CR12","doi-asserted-by":"publisher","first-page":"116016","DOI":"10.1016\/j.bone.2021.116016","volume":"150","author":"FS Kaplan","year":"2021","unstructured":"Kaplan FS, Teachey DT, Andolina JR, Siegel DM, Mancilla EE, Hsiao EC, et al. Off-on-off-on use of imatinib in three children with fibrodysplasia ossificans progressiva. Bone. 2021;150:116016. https:\/\/doi.org\/10.1016\/j.bone.2021.116016.","journal-title":"Bone"},{"key":"856_CR13","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1016\/j.bone.2017.07.019","volume":"109","author":"FS Kaplan","year":"2018","unstructured":"Kaplan FS, Andolina JR, Adamson PC, Teachey DT, Finklestein JZ, Ebb DH, et al. Early clinical observations on the use of imatinib mesylate in FOP: a report of seven cases. Bone. 2018;109:276\u201380. https:\/\/doi.org\/10.1016\/j.bone.2017.07.019.","journal-title":"Bone"},{"issue":"1","key":"856_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12891-022-05471-x","volume":"23","author":"BJ Smilde","year":"2022","unstructured":"Smilde BJ, Stockklausner C, Keen R, Whittaker A, Bullock AN, von Delft A, et al. Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP). BMC Musculoskelet Disord. 2022;23(1):1. https:\/\/doi.org\/10.1186\/s12891-022-05471-x.","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"856_CR15","doi-asserted-by":"publisher","first-page":"e95042","DOI":"10.1172\/jci.insight.95042","volume":"22","author":"E Williams","year":"2021","unstructured":"Williams E, Bagarova J, Kerr G, Xia DD, Place ES, Dey D, et al. Saracatinib is an efficacious clinical candidate for fibrodysplasia ossificans progressiva. JCI Insight. 2021;22(6):e95042. https:\/\/doi.org\/10.1172\/jci.insight.95042.","journal-title":"JCI Insight"},{"key":"856_CR16","doi-asserted-by":"publisher","unstructured":"Smolen JS, Landew\u00e9 RBM, Bijlsma JWJ, Burmester GR, Dougados M, Kerschbaumer A, McInnes IB, Sepriano A, van Vollenhoven RF, de Wit M, Aletaha D, Aringer M, Askling J, Balsa A, Boers M, den Broeder AA, Buch MH, Buttgereit F, Caporali R, Cardiel MH, De Cock D, Codreanu C, Cutolo M, Edwards CJ, van Eijk-Hustings Y, Emery P, Finckh A, Gossec L, Gottenberg JE, Hetland ML, Huizinga TWJ, Koloumas M, Li Z, Mariette X, M\u00fcller-Ladner U, Mysler EF, da Silva JAP, Po\u00f3r G, Pope JE, Rubbert-Roth A, Ruyssen-Witrand A, Saag KG, Strangfeld A, Takeuchi T, Voshaar M, van der Westhovens R. Heijde D. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655. Epub 2020 Jan 22.","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"856_CR17","doi-asserted-by":"publisher","unstructured":"Kostik MM, Raupov RK, Suspitsin EN, Isupova EA, Gaidar EV, Gabrusskaya TV et al. The Safety and Efficacy of Tofacitinib in 24 cases of Pediatric Rheumatic Diseases: single centre experience. Front Pediatr. (2022) 8;10:820586. doi: https:\/\/doi.org\/10.3389\/fped.2022.820586.","DOI":"10.3389\/fped.2022.820586"},{"key":"856_CR18","doi-asserted-by":"publisher","unstructured":"Nikishina I, Arsenyeva S, Matkava V, Kaleda M, Salugina S, Fedorov E et al. Tofacitinib in the therapy of different kind of pediatric rheumatic diseases: real clinical practice experience of a single center. In: Pediatr Rheumatol 20 (Suppl 2): 20 Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022); 2022 Sep 20\u201323; Prague, Czech Republic. P048, p.45. https:\/\/doi.org\/10.1186\/s12969-022-00729-z.","DOI":"10.1186\/s12969-022-00729-z"},{"issue":"10","key":"856_CR19","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1002\/jbmr.4655","volume":"37","author":"RJ Pignolo","year":"2022","unstructured":"Pignolo RJ, Baujat G, Hsiao EC, Keen R, Wilson A, Packman J, et al. Palovarotene for Fibrodysplasia Ossificans Progressiva (FOP): results of a Randomized, Placebo-Controlled, double-blind phase 2 trial. J Bone Miner Res. 2022;37(10):1891\u2013902. https:\/\/doi.org\/10.1002\/jbmr.4655.","journal-title":"J Bone Miner Res"},{"key":"856_CR20","doi-asserted-by":"publisher","unstructured":"Vanhoutte F, Liang S, Ruddy M, Zhao A, Drewery T, Wang Y, DelGizzi R, Forleo-Neto E, Rajadhyaksha M, Herman G, Davis JD. Pharmacokinetics and pharmacodynamics of Garetosmab (Anti-Activin A): results from a first-in-human phase 1 study. J Clin Pharmacol. 2020 Nov;60(11):1424\u201331. https:\/\/doi.org\/10.1002\/jcph.1638. Epub 2020 Jun 18.","DOI":"10.1002\/jcph.1638"}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-023-00856-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-023-00856-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T15:27:06Z","timestamp":1700321226000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-023-00856-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,29]]},"references-count":20,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["856"],"URL":"https:\/\/doi.org\/10.1186\/s12969-023-00856-1","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,29]]},"assertion":[{"value":"3 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written consent has been obtained from all parents\/guardians of minors according to the declaration of Helsinki. Patients were observed and treated during real clinical practice. The local Ethics Committee of V.A. Nasonova Research Institute of Rheumatology approved the study (09 Dec 2019).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors agree to publish the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors received spiker\u2019s fees for lectures.I.Nikishina: Pfizer, Roche, Novartis, Sobi, MSD, R-Pharm, Ipsen.S.Arsenieva: Pfizer, Novartis, Ipsen.V.Matkava: Pfizer, Novartis, Ipsen.A.Arefieva: none.M.Kaleda: Pfizer, Roche.A.Smirnov: Pfizer, Novartis, Janssen, Eli Lilly, R-Pharm, Biocad.L.Blank: none.M.Kostik: none.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"92"}}